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Abstract
A mathematical model is presented for the cellular
uptake and cytotoxicity of the anticancer drug doxo-
rubicin. The model assumes sigmoidal, Hill-type de-
pendence of cell survival on drug-induced damage.
Experimental evidence indicates distinct intracellular
and extracellular mechanisms of doxorubicin cyto-
toxicity. Drug-induced damage is therefore expressed
as the sum of two terms, representing the peak values
over time of concentrations of intracellular and extra-
cellular drugs. Dependence of cell kill on peak values
of concentration rather than on an integral over time
is consistent with observations that dose–response
curves for doxorubicin converge to a single curve as
exposure time is increased. Drug uptake by cells is
assumed to include both saturable and unsaturable
components, consistent with experimental data. Over-
all, the model provides better fits to in vitro cyto-
toxicity data than previous models. It shows how
saturation of cellular uptake or binding with concen-
tration can result in plateaus in the dose–response
curve at high concentrations and short exposure, as
observed experimentally in some cases. The model
provides a unified framework for analyzing doxoru-
bicin cellular pharmacokinetic and pharmacodynamic
data, and can be applied in mathematical models for
tumor response and treatment optimization.
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Introduction
Despite its toxicity, doxorubicin has been in clinical use
since the 1970s and remains a widely used anticancer
drug. No fully satisfactory mathematical model for doxo-
rubicin cellular pharmacokinetics and pharmacodynamics
has been proposed and validated. Cellular pharmacokinetic
models play an important role in predicting the penetra-
tion of drugs into tumor tissues. The penetration of doxo-
rubicin from microvessels into the tumor tissue is limited
by binding to extracellular sites as well as by cellular up-
take. This is especially important in regions of low vascular
density. Cellular pharmacodynamic models are needed in
the development of whole-body pharmacodynamic models
to predict drug response as a function of administration dos-
age and scheduling. Such predictions can then be used to
optimize therapy.
The use of prolonged infusion or fractionated doses of doxo-
rubicin has been justified on the grounds that the major dose-
limiting side effect, cardiotoxicity, is believed to depend on
peak drug levels, whereas the antitumor effect is assumed
to be a function of area under the concentration–time curve
(AUC) [1]. In actuality, the predictive value of AUC alone
for antitumor effect has not been thoroughly established.
Doxorubicin is classified by some researchers as cell cycle
phase–nonspecific, whereas others consider it a cell cycle
phase–specific drug. Ozawa et al. [2] proposed that cell kill
for cell cycle phase–nonspecific drugs is a function of the
(extracellular) AUC. AUC dependence had also been pro-
posed by Eichholtz-Wirth [3], who fit the following model for
cytotoxic effect of doxorubicin to data for Chinese hamster
and HeLa cells:
S ¼ expðktexpceÞ ð1Þ
In Eq. (1), S is survival relative to controls, k is a model
parameter that depends on the cell line, texp is exposure time,
and ce is extracellular concentration. El-Kareh and Secomb [4]
noted that several data sets in the literature do not support
the idea that cell kill is a function purely of AUC, but imply an
additional dependence on exposure time. Lankelma et al.
[5] also noted that, in general, cell uptake and cytotoxicity of
anticancer drugs depend on the shape of the concentration–
time curve.
Alternative models in the literature for drugs that do not
conform to AUC-dependent cytotoxicity include the CnT model
[6], the Hill equation–based model proposed by Levasseur
et al. [7], and the exponential cell kill model of Gardner [8]. All
these models involve extracellular drug concentration only,
and do not account for transport of drug into the cell. Although
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there is evidence that doxorubicin can kill cells without
entering them, intracellular drug is believed to make a sig-
nificant contribution to cell kill [9]. Cellular uptake data [10]
show that intracellular drug levels take hours to equilibrate
with extracellular levels, suggesting that the kinetics of up-
take affects cytotoxicity.
Some cellular pharmacodynamic models proposed in
the literature have included cellular pharmacokinetics. Lobo
and Balthasar [11] used a transit compartment model for
methotrexate that accounts for delays such as may result
from uptake, binding, or other processes that must occur
before a drug can act lethally. Their model is general in
that the delays are introduced as first-order reactions with-
out assigning any particular physical interpretation to any
of these processes. The mathematical assumption of first-
order kinetics rules out saturability in extracellular concen-
tration, a feature shown by the cellular uptake data [10].
Lankelma et al. [5] recently proposed a pharmacodynamic
model for doxorubicin that involves two intracellular compart-
ments, with cell kill a function of the concentration history
in the second compartment. In their model, concentration is
raised to a constant power n and appears in a ‘‘fading-
memory’’ integral giving cumulative cell damage. El-Kareh
and Secomb [12] proposed a cellular pharmacodynamic
model for cisplatin that related cell kill to the peak value
of time of an intracellular species, with the concentration of
this species determined by kinetic equations for drug uptake
and binding. Such a model could be applied to other drugs
by modifying the kinetic equations to reflect differences in
cellular uptake and target binding between drugs.
Of the abovementioned cellular pharmacodynamicmodels,
only that of Levasseur et al. [7] has been tested for doxoru-
bicin with cytotoxicity data that cover both multiple exposure
times and multiple concentrations. In that study, the data
included exposure times from 1 to 24 hours. Exposure time
dependence over this range was partly fitted by an expo-
nent (c) in their model, which is quadratic in exposure time.
This has the effect of causing the model to break down if
times beyond the range fitted are considered. At some ex-
posure time beyond 24 hours, the exponent changes sign,
causing the sigmoidal dose–response curves to invert and
become unrealistic [12]. This model also has the limitation
that it cannot readily be generalized to cases in which ex-
tracellular exposure is a function ce(t ) of time, as occurs
in vivo. In the study of Lankelma et al. [5], the exposure
times considered were 1, 3, and 7 days, and for each ex-
posure time only one extracellular concentration was used.
As discussed by El-Kareh and Secomb [4], cellular up-
take and cytotoxicity models can only be validated with
data sets that include multiple exposure times and multiple
concentration values.
The need remains for a cellular pharmacokinetic and
pharmacodynamic model for doxorubicin that can be vali-
dated with data for several different cell lines, that can be
used when the extracellular concentration varies with time,
and that is sufficiently simple to be of practical use. The
purpose of this paper is to develop such a model. Experi-
mental evidence implies two mechanisms of doxorubicin
cytotoxicity. The primary mechanism under clinical condi-
tions is believed to involve topoisomerase II inhibition by
intracellular drug, although a number of other mechanisms
have been proposed [1,9]. Drug that is rendered incapable
of entering cells also shows cytotoxicity, indicating a second
mechanism involving extracellular drug. Based on these
observations, a two-mechanism cellular pharmacodynamic
model is proposed.
Materials and Methods
Literature searches were performed to find cytotoxicity data
sets for doxorubicin that included at least three values of
exposure time, and for which the concentration covered a
range adequate to show the sigmoidal shape of the dose–
response curves. The data sets of Eliaz et al. [13] for mu-
rine melanoma cells, Levasseur et al. [7] for wild-type
A2780 human ovarian carcinoma cells, Link et al. [14] for
the HT29 and NMG64/84 human colorectal carcinoma cell
lines, Nguyen-Ngoc et al. [15] for mouse sarcoma cells,
Rupniak et al. [16] for human ovarian carcinoma cells iso-
lated from ascitic fluid, Vrignaud et al. [17] for rat glioblas-
toma cells, and Walker et al. [18] for human bladder cancer
cells were found to meet the criteria. The analysis was
restricted to in vitro studies because in vivo data on drug
uptake and cytotoxicity are confounded by many factors, in-
cluding transport of drug from plasma to the tumor cells, al-
tered drug response in the tumor interior due to the low-pH,
low-oxygen environment, and multicellular and confluent-
dependent resistance. In all cases, data points were read
manually from the graphs provided in the papers.
The pharmacodynamic model was developed based on
the following considerations. The damage done to a cell by
drug action is represented by a single continuous measure
D that depends on drug exposure. For an individual cell,
the possible outcomes are repair and survival if the damage
is below some threshold value, or death if the damage
exceeds the threshold. Mathematically, this can be repre-
sented by a step function dependence of survival on D. For
a population of cells, the threshold value is heterogeneous,
resulting in a sigmoidal variation in survival as a function of
dose or damage [7]. This distribution of damage threshold
values over the population is not known. However, it has
been found empirically that survival curves are well fitted
by a Hill equation, when plotted against drug concentra-
tion or other variables that are likely to measure or correlate
with damage. For this reason, a Hill equation is used here
to relate survival relative to controls to damage:
where A and n are constants.
The damage D is a function of drug concentration and
exposure time. A study including long exposure times [13]
showed that dose–response curves (response versus con-
centration for fixed exposure times) for doxorubicin con-
verge to a single curve as exposure time is increased. This
S ¼ 1
1þ A½Dn ð2Þ
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behavior is inconsistent with models in which D is a function
of AUC (area under the curve) of concentration only, be-
cause such dependence would cause the dose–response
curves to continue to shift to the left as exposure time
increases. By a similar argument, functions of either extra-
cellular or intracellular concentration integrated over the
exposure time can be ruled out as choices for D because
such functions would increase with exposure time, contra-
dicting the observed behavior. In the present model, D is
assumed to depend on peak values over time of concen-
trations of the species leading to cell kill. For a given extra-
cellular concentration, increases in exposure time beyond
that required to reach equilibrium intracellular drug levels
do not result in any further cell kill. As a result, the survival
curves converge to a single asymptotic curve in the limit of
long exposure time, as observed.
Much evidence points to topoisomerase II inhibition as
the main mechanism of doxorubicin-induced cell kill [9], but
some experimental studies have provided evidence for
an extracellular mechanism. Maestre et al. [19] compared
free drug with immobilized drug, which could not enter the
cell, and found that both were cytotoxic, with the former in-
ducing apoptosis, and the latter inducing necrosis. Based
on these observations, D is assumed to be the sum of two
terms—one dependent on the peak concentration ci
peak of
an intracellular species, and one on the peak concentration
ceb
peak of an extracellular membrane-bound species:
D ¼ ðc peaki Þm þ c peakeb ð3Þ
The exponent m allows for the fact that the heterogeneity
in sensitivity neednot be the same for both cell kill mechanisms.
As shown by uptake data of Kerr et al. [10], intracellular
levels of doxorubicin take hours to equilibrate with extra-
cellular levels. The kinetics of cellular uptake should there-
fore be considered. Doxorubicin is believed to enter cells
by passive transport mechanisms. The uptake data indicate
saturation in extracellular concentration, which has been
interpreted as an indication either of carrier-mediated trans-
port [20] or of self-association in the extracellular environ-
ment [1]. Based on these observations, the following cellular
pharmacokinetic model is proposed, in which the uptake
rate is a combination of a linear diffusive component and a
saturable, carrier-mediated component:
dc i
dt
¼ k3 k1ce þ k2ce
Ki þ ce  ci
 
ð4Þ
In Eq. (4), ce is the concentration of free extracellular
drug. The parameter k1 gives the ratio of intracellular to
extracellular concentration at which the net rate of passive
exchange is zero. This parameter is not necessarily equal to
one because intracellular and extracellular concentrations
are generally measured in different units, and conversion
often involves assumptions about cell volume, or the relation
between fluorescence and concentration, which are not pre-
cisely known. Furthermore, intracellular binding or seques-
tration allows intracellular concentrations of doxorubicin to
be much higher than extracellular concentrations at equilib-
rium. The model of Eq. (4) was fitted to cellular uptake data
[10] to obtain values for the parameters k1, k2, Ki, and k3. In
fitting these model parameters to the data, the root mean
square (RMS) deviation of the predicted values and the
data points was minimized by using a numerical function
minimization routine of the Mathematica software package
(Wolfram Research, Champaign, IL).
For cases in which extracellular concentration ce(t ) varies
with time, ci
peak is determined by solving Eq. (4) for ci(t ) and
by determining the peak value that this function takes over
time. For the in vitro experimental cytotoxicity data sets used
to test the model, ce was held constant for an exposure time
texp, and then reduced to zero. For this type of exposure:
c peaki ¼ k1ce þ
k2ce
Ke þ ce
 
ð1 exp½k3texpÞ ð5Þ
Because formation of an extracellular bound species in-
volves binding and no transport across the membrane, the
concentration of extracellular membrane-bound species is
assumed to equilibrate rapidly and therefore to be described
by a Michaelis-Menten equation:
c peakeb ¼
k4ce
Ke þ ce ð6Þ
The saturability inherent in Eqs. (5) and (6) accounts for
the fact that the numbers of membrane transporters and ex-
tracellular binding sites available for doxorubicin are finite.
It is compatible with the plateaus seen in some dose–
response curves for doxorubicin at high concentrations. Sub-
stituting the expressions for peak concentrations obtained
from Eqs. (5) and (6) in Eqs. (2) and (3) gives an expression
for survival relative to controls:
S ¼ 1
1þA k1þ k2ceKiþce
 
ð1 expðk3texpÞÞ
 mþ k4ceKeþce
h in ð7Þ
This two-mechanism peak concentration model was fit
to each of the eight cytotoxicity data sets from the literature
to estimate the unknown parameters by minimizing the
mean square deviation between predicted and experimental
data points as described above. When uptake parameters
are not available from separate data, the parameter A is not
independent of the other parameters in Eq. (7). The value 1
was therefore assigned to A, and the eight remaining param-
eters were obtained by fitting. For purposes of comparison,
seven other previous models were also fitted to the same
data sets. These include the AUC-dependent model [3]
(Eq. (1)) and the CnT Hill model [6]:
S ¼ 1
1þ AðCnT Þm ð8Þ
Because dose–response curves are often fitted to Hill
equations rather than exponentials, another AUC-dependent
model, the ‘‘extracellular AUC Hill model’’:
S ¼ 1
1þ AðAUCeÞn
ð9Þ
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was tested as an alternative to Eichholtz-Wirth’s model. The
models of Levasseur et al. [7] and Gardner [8] were also
tested. Gardner’s study proposes two models—one for cell
cycle phase–specific drugs and one for phase–nonspecific
drugs. Because doxorubicin has, at times, been classified
either way in the literature, both models were tested.
Results
Figure 1 shows the fit of the uptake model (Eq. (4)) to data
for the cellular uptake of doxorubicin by non-small cell lung
tumor cells [10]. The data clearly show the initial saturation,
followed by continued linear uptake, in agreement with
Eq. (4). The best model fit, with parameter values k1 =
0.00631 (ng/105 cells)/(mg/ml), k2 = 0.126 ng/10
5 cells, Ki =
0.528 mg/ml, and k3 = 1.01 hr
1, shows good agreement.
When either the saturable or the nonsaturable uptake term
was omitted in Eq. (4), the resulting fits were significantly
inferior, confirming that both terms are needed.
RMS residual errors for the fit of the present two-
mechanism peak concentration model and seven other
models to eight data sets for doxorubicin cytotoxicity are
shown in Table 1. In all but two cases, the present model
gave lower residual errors than the other models. For the
data set of Levasseur et al. [7], the CnTmodel and the single
and double Hill models [7] gave slightly smaller values for
the RMS residual. For the data set of Vrignaud et al. [17], the
double Hill model [7] gave slightly smaller residuals. In no
case did any other model give a significantly (more than .01)
lower residual than the present model. The Wilcoxon signed
rank one-tailed test was performed using the RMS devia-
tion values in Table 1, from which it was determined that
the two-mechanism peak concentration model was superior
to the CnTmodel (significance level P = .004), the Levasseur
et al. single Hill model (P = .008), and the Levasseur et al.
double Hill model (P = .012).
The fitted parameters for the two-mechanism peak con-
centration model are given in Table 2. In each case, A = 1.
The parameter Ki, which indicates the concentration at which
the intracellular uptake saturates, is small in all cases, indi-
cating that this binding or transport step has a high affinity
for the drug. In the data sets of Rupniak et al. [16] and
Walker et al. [18], high values of Ke were obtained, indicat-
ing that the effect of extracellularly bound drug is nonsatu-
rating over the range of concentrations considered.
Model fits to the data for the present two-mechanism
peak concentration model, the CnT model, and the single
or double Hill equation model [7], are shown for several data
sets in Figures 2 –6. The present model is able to represent
the ‘‘plateau’’ in survival that is seen in some data sets at high
concentrations and short exposure times (Figures 2 and 5).
This arises in the model because the saturable component
of cellular uptake reaches its maximal level, and increased
uptake can only be achieved through the nonsaturable
pathway, which is relatively inefficient.
The improved ability of the two-mechanism peak con-
centration model to fit the data, relative to previously pro-
posed models, is most evident for data sets covering broad
ranges of exposure times [13,15,17] (Figures 2, 4, and 5).
Conversely, the data of Walker et al. [18] (Figure 6) cover
a limited range of exposure times (30 minutes to 2 hours),
and all the models considered yield RMS deviations of
about .05 or less. This is likely due to the fact that, over
Figure 1. Cellular pharmacokinetic model fit to cellular uptake data of Kerr
et al. [10] for doxorubicin in non-small cell lung tumor cells.
Table 1. RMS Deviations of Model Fits to Cytotoxicity Data for Doxorubicin Acting on Various Cancer Cell Lines.
Data Set Two-Mechanism
Peak
Concentration
Model
Extracellular
AUC (Hill
Equation)
Extracellular
AUC
(Exponential;
Eichholtz-
Wirth [3])
CnT Levasseur et al. [7]
(Single Hill
Equation)*
Levasseur et al. [7]
(Double Hill
Equation)*
Gardner [8]
Cell Cycle–
Nonspecific
Gardner [8]
Cell Cycle –
Specific
Number of parameters 8 2 1 3 6* 12* 2 3
Eliaz et al. [13] 0.0317 0.102 0.113 0.0996 0.0950 0.0937 0.101 0.0961
Levasseur et al. [7] 0.119 0.131 0.130 0.113 0.112 0.110 0.128 0.128
Link et al. [14] HT29 cells 0.0397 0.0943 0.115 0.0921 0.0803 0.0595 0.115 0.0668
Link et al. [14] NMG64/84 cells 0.0814 0.0952 0.136 0.0937 0.0998 0.0998 0.131 0.131
Nguyen-Ngoc et al. [15] 0.0426 0.123 0.148 0.0689 0.0644 0.0598 0.148 0.0711
Rupniak et al. [16] 0.0425 0.201 0.246 0.0541 0.0535 0.0535 0.246 0.101
Vrignaud et al. [17] 0.0494 0.169 0.186 0.0972 0.0560 0.0471 0.186 0.186
Walker et al. [18] 0.0141 0.0269 0.0537 0.0261 0.0255 0.0255 0.0537 0.0537
*The Levasseur et al. [7] single and double Hill models have 7 and 13 parameters, respectively, but the parameter Econ was constrained to force survival relative to
controls to equal 1 at zero concentration.
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a limited range of exposure times, one of the two mecha-
nisms of cell kill is dominant. Inclusion of both mechanisms
becomes more important when wide ranges of exposure
times are included.
Discussion
The present cellular pharmacokinetic model (Eq. (4)) pro-
vides a good fit to data for uptake by non-small cell lung
cancer cells [10]. The model is further supported by data
on doxorubicin uptake by Chinese hamster ovary cells [21],
which also show uptake as a function of extracellular con-
centration at a fixed exposure time first increasing rapidly
and nonlinearly, and then linearly at a slower rate at higher
concentrations. Bates et al. [21] hypothesized that doxo-
rubicin enters the cell only by passive diffusion, but at lower
concentrations much of it is taken up rapidly by high-affinity
binding sites. At higher concentrations, these binding sites
are saturated and additional drug taken up by the cell re-
mains unbound in the intracellular space, giving a linear
uptake behavior. The model proposed here predicts the
same behavior observed by Bates et al. [21], although here
the saturability is interpreted in terms of a carrier for trans-
membrane transport rather than intracellular binding sites.
The model of Eq. (7) relates drug effect to the peak
value of total intracellular concentration (as well as that of
an extracellular species). In reality, nuclear doxorubicin is
likely responsible for the primary intracellular mechanism
of cell kill, namely topoisomerase II inhibition. The fact that
we found peak total intracellular concentration to be a good
predictor of drug activity may reflect a rapid equilibration of
nuclear, DNA-bound doxorubicin with the free intracellular
drug, so that the peak value of DNA-bound drug is propor-
tional to that of total intracellular drug.
A unique feature of the model proposed here is that
the dose–response curves converge to a single asymptotic
curve as the exposure time is increased. This behavior has
been observed for doxorubicin and other chemotherapeutic
drugs including paclitaxel [22]. In the model, it results from
the assumption that cell kill depends on peak concentra-
tions. In models in which cell kill depends on a time integral
of concentration, the survival fraction approaches zero as ex-
posure time is increased. Several researchers [8,11,23–25]
have described the rate of chemotherapeutic drug-induced
cell kill relative to the population size as a function of the
instantaneous extracellular drug concentration only. In such
models, the survival fraction similarly approaches zero as
exposure time increases.
Relative to the present model, the Hill equation models
of Levasseur et al. [7] give comparable fits to some expe-
rimental cytotoxicity data sets [7,17] based on the RMS
residual values (Table 1). In some cases, however, the re-
sulting survival curves intersect (Figures 2 and 5). This im-
plies behavior in which increasing dose leads to increasing
survival, which can only occur if the drug is self-inhibiting.
The double Hill equation model of Levasseur et al. [7]
can also show abrupt changes in survival with concentra-
tion (Figure 5), which are unlikely to be realistic. The two-
mechanism peak concentration model does not show these
types of behavior. Of the other models considered, the CnT
model generally gives the next best fits to the experimental
data. When n > 1, this model gives a cell kill that depends
more strongly on concentration than on exposure time. In
this sense, it approaches the behavior of the present model,
in which cell kill depends only on concentration when the
exposure time is long enough.
The present model contains a relatively large number
of unknown parameters (eight). This number of parame-
ters is needed to represent the observed behavior in cases
where a plateau in survival occurs at high concentrations
and short exposure times [13,17]. By comparison, the double
Hill model [7], which can also represent such behavior,
requires 12 unknown parameters. For some of the data
sets [7,18], it was found that a simplified version of Eq. (7)
with three independent unknown parameters:
S ¼ 1
1þ A k1 1 expðk3texpÞ
  	n ð10Þ
could fit the data almost equally well. In these cases, the
plateau in survival was not seen, either because the range
of exposure times was too limited or because different cell
lines were used. The saturation in extracellular concentra-
tion shown by the Kerr et al. [10] uptake data is absent in
Eq. (10), probably reflecting the fact that the data sets [7,18]
covered limited ranges of concentration, over which uptake
could be well approximated as nearly linear in ce. In Table 2,
Table 2. Model Parameter Values Obtained from Fit to Data.
Data Set k1 k2 Ki k3 k4 Ke m n
Eliaz et al. [13] 0.0004926 0.9626 0.0003385 0.2932 1.191 0.2198 8.444 5.511
Levasseur et al. [7] 5.527 3.350 0.01593 0.06189 2.881 3.817 0.3950 5.878
Link et al. [14] HT29 cells 22.76 5.840 0.0009478 0.01450 1.495 0.1185 0.4578 3.979
Link et al. [14] NMG64/84 cells 5.952 0.8406 0.00003644 0.7725 0.2842 0.005309 0.2147 10.68
Nguyen-Ngoc et al. [15] 0.2257 1.299 5.711  106 0.1549 1.240 0.6210 0.3594 4.809
Rupniak et al. [16] 34.78 0.6003 1.252  107 0.03845 2784 429.7 4.845 0.7418
Vrignaud et al. [17] 9.227  106 2.417 0.07207 1.205 1.581 1.148 0.6818 3.886
Walker et al. [18] 0.1048 0.9885 0.002017 3.026 2301 1352 25.89 2.136
Parameter values are based on fits to Eq. (7) with concentrations measured in micrograms per milliliter, and time in hours, except for the Levasseur et al. [7] data
set, for which concentration is in micromolars.
In each case, A = 1.
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all the parameters for the model of Eq. (7) were given for
consistency. For those data sets for which the simplified
model of Eq. (10) provides an equally good fit, not all the
parameters in Table 2 are individually meaningful, in the
sense that other combinations of parameters could provide
an equally good fit to the data.
Plateaus in the survival curve at high concentrations, as
seen in Figures 2 and 5, have been discussed previously
[26]. Disappointing results from high-dose chemotherapy
with agents such as doxorubicin have been attributed to
this effect [27]. Gardner [8] interpreted such plateaus as
evidence of cell cycle phase specificity, reasoning that, at
short exposure times, a fraction of the cells is not in the
sensitive phase during exposure, so that cell kill is incom-
plete even at high concentrations. However, the cell cycle
phase–specific model based on this concept [8] does not
give a good fit to the data sets considered here showing
such behavior [13,17].
In some cases, a further decline in survival at higher
concentrations is seen, giving a ‘‘double sigmoidal’’ curve
with two inflection points. Such behavior was observed by
Figure 3. Cellular pharmacodynamic model fits to data of Levasseur et al. [7]
for doxorubicin effect on wild-type A2780 human ovarian carcinoma cells. (A)
Two-mechanism peak concentration model. (B) CnT model. (C) Single Hill
model of Levasseur et al. [7].
Figure 2. Cellular pharmacodynamic model fits to data of Eliaz et al. [13] for
B16F10 murine melanoma cells. (A) Two-mechanism peak concentration
model. (B) CnT model. (C) Single Hill model of Levasseur et al. [7]. For the
exposure times 24, 48, 72, and 96 hours, the data overlapped and only one
symbol is visible. The model prediction curves also coincide.
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Levasseur et al. [7] for paclitaxel and for the response of
resistant cell lines to methotrexate, raltitrexed, and AG2034,
although not for doxorubicin. They remarked that this phe-
nomenon could be attributed to the existence of two or
more intracellular drug targets, but considered it more likely
to result from cellular heterogeneity. Their model is based
on the superposition of two Hill equations representing
two populations of different drug sensitivities. Such behavior
can occur in the present model, as seen in Figure 2A
for data at 6 hours [13]. It results from including both satu-
rable and nonsaturable terms in the cellular uptake kinetics
(Eq. (4)). At low concentrations, the saturable uptake term in
Eq. (4) is dominant. The dose–response curve initially levels
off when this saturable uptake term reaches saturation with
increasing concentration. Then, as the nonsaturable uptake
term becomes dominant, the survival curve declines again.
Given that wild cell populations are likely to have a con-
tinuous spectrum of sensitivities rather than two distinct
subpopulations, the present model appears to provide a
more satisfactory explanation for such behavior.
Figure 4. Cellular pharmacodynamic model fits to doxorubicin cytotoxic-
ity data of Nguyen-Ngoc et al. [15] for mouse sarcoma cells. (A) Two-
mechanism peak concentration model. (B) CnT model. (C) Single Hill model
of Levasseur et al. [7].
Figure 5. Cellular pharmacodynamic model fits to data of Vrignaud et al. [17]
data for doxorubicin cytotoxic effect on rat glioblastoma cells. (A) Two-
mechanism peak concentration model. (B) CnT model. (C). Double Hill model
of Levasseur et al. [7].
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According to the present model, survival is predicted to
approach zero for sufficiently high concentrations if a non-
saturable uptake mechanism is available (i.e., if k1 is non-
zero in Eq. (7)). This is the case for the fit to the data of
Eliaz et al. [13], as shown in Figure 2A. However, the data
of Vrignaud et al. [17] give a value of k1 very close to zero
and the survival curves show a plateau with no second
inflection point for the range of concentrations used
(Figure 5A). Neither data set has sufficient data points at
very high concentrations to definitively show the eventual
behavior. Also, none of the data sets considered here
resolves survival fractions relative to controls below 1%,
and plateaus may be present at very low survival. Further
data are needed to determine the possible role of this plateau
effect in clinical trials of high-dose doxorubicin.
At high drug concentrations, significant cytotoxicity is ob-
served even for exposure times of 1 hour or less (Figures 3–6).
Such exposure times are much shorter than cell cycle
times, which are typically about 20 hours or more for the cell
lines considered [7,13,14,17,18]. Topoisomerase II inhibition
is considered to be the main mechanism of doxorubicin-
induced cell kill [9], and this mechanism may only be ef-
fective if the drug is present when cells pass through a
specific phase of the cell cycle. Therefore, it might seem
surprising that a large cell kill could be achieved with short
exposure times. However, it should be noted that the mea-
surements of cell survival are made well after the time of
exposure, typically 1 to 4 days [13,15,16,18]. The present
peak concentration model is consistent with the concept
that a drug remains bound to nuclear structures after cellular
exposure to the drug has ended, and has its effect during
subsequent cell cycles.
The present model is a step toward understanding and
quantifying the relation between drug administration and
tumor response for the widely used anticancer drug, doxo-
rubicin. The model is for cells in culture, where oxygenation,
pH, cell density, cell attachment, and proliferation status are
generally different than within tumors. Such factors may
influence cytotoxicity [28,29]. In addition, plasma exposure
and cellular exposure may differ significantly in vivo because
of limitations in drug transport. Changes in cellular uptake
or efflux of drug are important factors in cellular resistance
to doxorubicin [30]. By explicitly representing the cellular
uptake process and the sensitivity to the drug at a given
intracellular level, the model proposed here provides a basis
for analyzing experimental data obtained under conditions
more representative of the physiological tumor environ-
ment. It is expected that this model will have use in future
mathematical modeling of the response and optimization
of doxorubicin chemotherapy.
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